Study summary

A first-in-class pill shrank mesothelioma in about a quarter to a third

VT3989 early trial · Phase 1/2 · Published October 2025, Nature Medicine

26%of 47 people with mesothelioma had tumors shrink

What was tested

VT3989, a pill that blocks TEAD, a switch in the Hippo pathway that is broken in most mesotheliomas, in an early trial.

What they found

Tumors shrank in 26% of 47 people with mesothelioma at optimized doses.
With refined dosing rules, 32% responded and median time before growth was 10 months.

What it means

The first targeted drug with real activity in mesothelioma. A phase 3 trial is planned.

Nat Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.